Table 2. Patient outcomes . Arm A:... | American Society of Hematology

Table 2.

Patient outcomes

	Arm A: decitabine (n = 82)	Arm B: decitabine + bortezomib (n = 81)	P (2 sided)
n (%; 95% CI) achieving CR + CRi rate	32 (39; 28-50)	31 (38; 28-50)	.91*
Median (range) time to response, mo	3.6 (0.9-17.2)	2.3 (1.7-7.9)	.32†
Median (95% CI) duration of response, CR + CRi, mo‡	10.9 (5.7-19.6)	15.3 (10.4-NA)	.15§
Median (95% CI) OS, mo‡	9.3 (5.8-12.2)	8.9 (3.8-14.3)	.18‖
Median (95% CI) OS after transplantation, mo¶	NA (n = 9)	31.1 (4.6-NA)	.98§

	Arm A: decitabine (n = 82)	Arm B: decitabine + bortezomib (n = 81)	P (2 sided)
n (%; 95% CI) achieving CR + CRi rate	32 (39; 28-50)	31 (38; 28-50)	.91*
Median (range) time to response, mo	3.6 (0.9-17.2)	2.3 (1.7-7.9)	.32†
Median (95% CI) duration of response, CR + CRi, mo‡	10.9 (5.7-19.6)	15.3 (10.4-NA)	.15§
Median (95% CI) OS, mo‡	9.3 (5.8-12.2)	8.9 (3.8-14.3)	.18‖
Median (95% CI) OS after transplantation, mo¶	NA (n = 9)	31.1 (4.6-NA)	.98§

NA, not attained.

Mantel-Haenszel test.

Two-sided rank sum test.

Kaplan-Meier estimate.

Two-sided stratified log-rank test.

One-sided stratified log-rank test.

Landmark Kaplan-Meier estimate from time of transplantation to death resulting from any cause.